Klechevsky; Eynav

Patent Applications and Registrations

Patent applications and USPTO patent grants for Klechevsky; Eynav.The latest application filed is for "methods and compositions for t cell activation".

Company Profile

0.13.19

Klechevsky; Eynav - St. Louis MO US
Klechevsky; Eynav - Haifa IL
Klechevsky; Eynav - Dallas TX

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Detection of CD5 and methods and compositions for modulating CD5 Grant 11,369,663 - Klechevsky June 28, 2	2022-06-28
Methods And Compositions For T Cell Activation App 20210163894 - KLECHEVSKY; Eynav ; et al.	2021-06-03
Detection Of Cd5 And Methods And Compositions For Modulating Cd5 App 20190216897 - Klechevsky; Eynav	2019-07-18
Vaccines directed to langerhans cells Grant 9,315,580 - Banchereau , et al. April 19, 2	2016-04-19
Multivariable Antigens Complexed With Targeting Humanized Monoclonal Antibody App 20160031988 - Zurawski; Gerard ; et al.	2016-02-04
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells Grant 9,234,040 - Zurawski , et al. January 12, 2	2016-01-12
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells Grant 9,102,730 - Zurawski , et al. August 11, 2	2015-08-11
Immunoadjuvant compounds and uses thereof Grant 9,061,066 - Gorvel , et al. June 23, 2	2015-06-23
Vaccines Based On Targeting Antigen To Dcir Expressed On Antigen-presenting Cells App 20140134168 - Zurawski; Gerard ; et al.	2014-05-15
Vaccines Directed To Langerhans Cells App 20140030264 - Banchereau; Jacques F. ; et al.	2014-01-30
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells Grant 8,586,052 - Zurawski , et al. November 19, 2	2013-11-19
Vaccines Based On Targeting Antigen To Dcir Expressed On Antigen-presenting Cells App 20130295120 - Zurawski; Gerard ; et al.	2013-11-07
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells Grant 8,449,888 - Zurawski , et al. May 28, 2	2013-05-28
Novel Immunoadjuvant Compounds And Uses Thereof App 20130129756 - Gorvel; Jean-Pierre ; et al.	2013-05-23
Immunoglobulin-like Transcript (ilt) Receptors As Cd8 Antagonists App 20120315269 - Klechevsky; Eynav ; et al.	2012-12-13
Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells App 20120237513 - Zurawski; Gerard ; et al.	2012-09-20
Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells App 20120004643 - Zurawski; Gerard ; et al.	2012-01-05
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells Grant 8,057,798 - Zurawski , et al. November 15, 2	2011-11-15
Dendritic Cell Immunoreceptors (dcir)-mediated Crosspriming Of Human Cd8+ T Cells App 20110274653 - Banchereau; Jacques F. ; et al.	2011-11-10
Vaccines Directed To Langerhans Cells App 20110081343 - Banchereau; Jacques F. ; et al.	2011-04-07
Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody App 20100330115 - Zurawski; Gerard ; et al.	2010-12-30
Multivariable antigens complexed with targeting humanized monoclonal antibody Grant 7,786,267 - Zurawski , et al. August 31, 2	2010-08-31
Antibodies, Methods And Kits For Diagnosing And Treating Melanoma App 20100158927 - Reiter; Yoram ; et al.	2010-06-24
Antibodies for selective apoptosis of cells App 20100062001 - Reiter; Yoram ; et al.	2010-03-11
Anti-cd8 Antibodies Block Priming Of Cytotoxic Effectors And Lead To Generation Of Regulatory Cd8+ T Cells App 20090304659 - Banchereau; Jacques F. ; et al.	2009-12-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.